PITTSBURGH — Mylan Inc. has launched bupropion hydrochloride extended-release tablets, indicated for the treatment of depression.
The drug maker said Friday that its Mylan Pharmaceuticals Inc. subsidiary released launched bupropion hydrochloride extended-release tablets USP in 150-mg and 300-mg doses, which are taken once each day.
Mylan said the new product is the generic version of GlaxoSmithKline’s antidepressant Wellbutrin XL.
Bupropion hydrochloride extended-release tablets had U.S. sales of about $752 million for the 12 months ended June 30, according to IMS Health data cited by Mylan.
